Skip To Main Content
Rami S. Komrokji on Muck Rack

Rami S. Komrokji

As seen in: Nature, Wiley, Wiley Online Library, The University of New Mexico - UNM, The Lancet, Healio, Blood, Ash Publications, Future Medicine, OncLive and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rami S.

Contact Rami S., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database

|
By Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Tulika Gupta, Jessica M. Stempel, Najla Al Ali, Amy E. DeZern, Mikkael Sekeres, Geoffrey L Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew Brunner, Christine McMahon, Rory M. Shallis, Joshua F. Zeidner, Michael Savona, Constantine N Logothetis, Aram Bidikian, Gail J. Roboz, Benjamin Rolles, Eunice Wang, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David A Sallman, Anoop K. Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, María Díez-Campelo, David Valcárcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Maximilian Stahl, Rami S. Komrokji, Amer M Zeidan, Hayley Hawkins, Namrata Sonia Chandhok, Ted M. Getz, Amyah C. Harris, Jaclynn Campos
| Nature Verified
Abstract Monotherapy with hypomethylating agents (HMA) remains the standard of care for patients with higher-risk myelodysplastic neoplasms (HR-MDS). Recently, the randomized phase III VERONA study evaluating azacitidine plus venetoclax (VEN) versus azacitidine plus placebo in newly diagnosed HR-MDS showed no difference in overall survival (OS) between the two arms. However, whether the addition of VEN to HMA improves outcomes among subsets of patients with HR-MDS remains debated.
Open in Who Shared Issue with article?

Data-Driven, Harmonised Classification System for Myelodysplastic Syndromes: A Consensus Paper From the International Consortium for Myelodysplastic Syndromes

|
By Rami S. Komrokji
| The University of New Mexico - UNM
Komrokji RS, Lanino L, Ball S, Bewersdorf JP, Marchetti M, Maggioni G, Travaglino E, Al Ali NH, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain AG, Aguirre LE, Tinsley-Vance SM, Schwabkey ZI, Chan O, Xie Z, Brunner AM, Kuykendall AT, Bennett JM, Buckstein R, Bejar R, Carraway HE, DeZern AE, Griffiths EA, Halene S, Hasserjian RP, Lancet J, List AF, Loghavi S, Odenike O, Padron E, Patnaik MM, Roboz GJ, Stahl M, Sekeres MA, Steensma DP, Savona MR, Taylor J, Xu ML, Sweet K,...
Open in Who Shared Issue with article?

How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

|
By Maria Julia Montoro, Pamela Acha, Claudia Haferlach, Onyee Chan, Víctor Navarro Verified, Yasuo Kubota, Felicitas Schulz, Robert Briski, Najla Al Ali, Blanca Xicoy, Laura F. Palomo, Francesc Bosch, Manja Meggendorfer, Teresa Gonzalez, Andrés Jerez, Alessia Campagna, Valeria Santini, Teresa Bernal, Esperanza Such, Tariq Kewan, Carmelo Gurnari, Austin G. Kulasekararaj, Maria Teresa Voso, Mikkael Sekeres, Aref Al-Kali, Elisa Diral, Mara Memoli, Uwe Platzbecker, Amer M Zeidan, María Díez-Campelo, Guillermo Garcia-Manero, Daniel H. Wiseman, Matteo Della Porta, Ulrich Germing, Jaroslaw Maciejewski, Rami S. Komrokji, Francesc Solé, Torsten Haferlach, Pierre Fenaux, David Valcárcel, Felix López-Cadenas, Lea Naomi Eder, YuHung Wang, Beate Betz, Anne Sophie Platzbecker, Carla Zindel, Nicolas Díaz-Varela, Antonella Polini, Detlef Haase
| Nature Verified
Abstract Myelodysplastic neoplasms (MDS) with TP53 multihit alterations are associated with dismal outcomes. MDS with isolated del(5q) present favorable prognosis but is defined by the absence of TP53 multihit alterations. However, whether TP53 multihit alterations exert the same adverse impact in this genetic context remains uncertain.
Open in Who Shared Issue with article?
See all 34 licensed articles (57 Total)